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Abstract
Background: With the development of new specific inhibitors of hepatitis C virus (HCV) enzymes and functions that may
yield different antiviral responses and resistance profiles according to the HCV subtype, correct HCV genotype 1 subtype
identification is mandatory in clinical trials for stratification and interpretation purposes and will likely become necessary in
future clinical practice. The goal of this study was to identify the appropriate molecular tool(s) for accurate HCV genotype 1
subtype determination.
Methodology/Principal Findings: A large cohort of 500 treatment-naı ¨ve patients eligible for HCV drug trials and infected
with either subtype 1a or 1b was studied. Methods based on the sole analysis of the 59 non-coding region (59NCR) by
sequence analysis or reverse hybridization failed to correctly identify HCV subtype 1a in 22.8%–29.5% of cases, and HCV
subtype 1b in 9.5%–8.7% of cases. Natural polymorphisms at positions 107, 204 and/or 243 were responsible for mis-
subtyping with these methods. A real-time PCR method using genotype- and subtype-specific primers and probes located
in both the 59NCR and the NS5B-coding region failed to correctly identify HCV genotype 1 subtype in approximately 10% of
cases. The second-generation line probe assay, a reverse hybridization assay that uses probes targeting both the 59NCR and
core-coding region, correctly identified HCV subtypes 1a and 1b in more than 99% of cases.
Conclusions/Significance: In the context of new HCV drug development, HCV genotyping methods based on the exclusive
analysis of the 59NCR should be avoided. The second-generation line probe assay is currently the best commercial assay for
determination of HCV genotype 1 subtypes 1a and 1b in clinical trials and practice.
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Introduction
Over 170 million individuals are infected with hepatitis C virus
(HCV) worldwide. Phylogenetic analyses have shown that HCV
strains can be classified into at least 6 major genotypes (numbered
1 to 6), and a large number of subtypes within each genotype [1].
Genotype 1 is by far the most frequent genotype in chronically
infected patients worldwide, with subtypes 1a and 1b representing
the vast majority of circulating strains [2,3,4].
Current treatment of chronic hepatitis C is based on the
combination of pegylated interferon (IFN)-a and ribavirin [5].
This treatment fails to eradicate infection in 50%–60% of patients
infected with HCV genotype 1 and approximately 20% of those
infected with HCV genotypes 2 and 3 [6,7,8]. Thus the need for
more efficacious therapies is urgent, especially for patients infected
with HCV genotype 1. A number of novel antiviral molecules
currently are in preclinical or clinical development [9]. The most
advanced ones are specific inhibitors of viral enzymes and
functions involved in the HCV life cycle. Molecules that have
reached clinical development include inhibitors of the nonstruc-
tural (NS) 3/4A serine protease and inhibitors of HCV replication
that belong to different categories: nucleoside/nucleotide analogue
and non-nucleoside inhibitors of the HCV RNA-dependent RNA
polymerase (RdRp), NS5A inhibitors and cyclophilin inhibitors
[9]. These agents have shown potent antiviral efficacy when used
alone, and encouraging results have been recently published
showing that HCV clearance can be achieved in approximately
70% of cases when a potent NS3/4A inhibitor is used in
combination with pegylated IFN-a and ribavirin [10,11,12].
HCV genotype 1 is generally considered as a homogeneous
group. There are however biological differences between the
different subtypes of HCV genotype 1, which are related to
differences in their nucleotide and amino acid sequences.
Importantly, differences between subtype 1a and 1b (by far the
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practice) include different efficacies of antiviral drugs and
different resistance profiles to such drugs. Indeed, several HCV
inhibitors appear to have selective activity against different HCV
genotype 1 subtypes, both in vitro and in vivo. Differences have
been observed in vitro with NS3/4A protease inhibitors, non-
nucleoside inhibitors of HCV RdRp and NS5A inhibitors
[13,14,15,16,17]. For instance, BILB 1941, a non-nucleoside
inhibitor of HCV RdRp, has been shown to have better antiviral
efficacy in patients infected with HCV subtype 1b than in those
infected with HCV subtype 1a, a finding reflecting in vitro
experiments [13].
A major issue that limits the efficacy of direct acting antiviral
therapies for HCV is the selection by these drugs of resistant
variants upon administration [18]. Recent studies with NS3/4A
protease inhibitors have shown that the genetic barrier and
resistance profiles substantially differ between the different
genotype 1 subtypes. For instance, the Arg to Lys substitution at
position 155 of the NS3 protease (R155K) is usually selected in
subtype 1a replicons treated with telaprevir, but not in subtype 1b
replicons [19]. The reason is that only one nucleotide substitution
is needed relative to the subtype 1a sequence to generate this
variant, whereas two substitutions are needed relative to the 1b
sequence (codon usage bias). Overall, natural polymorphisms at
positions R155 and V36 are frequent in subtype 1a, but rare in
subtype 1b where substitutions at position A156 are preferentially
selected in vitro [19]. This is reflected in vivo by the different
resistance profiles in patients infected by HCV subtypes 1a and 1b.
In the former, the V36 and R155 substitutions represent the
backbone of resistance, whereas in the latter resistance is less
frequent as it is preferentially associated with substitutions at
position A156 that are associated with a decreased fitness of the
variants [19,20,21]. Similarly, important differences in the
resistance profiles have been described in vitro with HCV-796, a
non-nucleoside inhibitor of HCV RdRp. The C316Y amino acid
substitution has been reported to be selected in both subtype 1a
and 1b replicon cells. However, in genotype 1a replicons, the
C316Y substitution has low replication capacity that must be
compensated for by additional ‘‘compensatory’’ substitutions,
including L392F or M414T, resulting in an increase in replication
levels of at least 10-fold [19]. A higher genetic barrier to resistance
to HCV-796 and related compounds is therefore expected in
patients infected with HCV subtype 1a than 1b. In vivo, HCV-796
monotherapy was however shown to select subtype 1a variants
with a single C316Y substitution, whereas the C316Y substitution
was associated with a number of additional substitutions in subtype
1b patients [22].
As a result of these findings, correct identification of HCV
subtypes 1a and 1b is crucial in clinical trials assessing new HCV
drugs in order to correctly stratify and interpret efficacy and
resistance data. It may also become important in future clinical
practice, as tailoring treatment schedules with HCV inhibitors to
HCV genotype 1 subtype might become necessary. A variety of
molecular methods can be used to identify the HCV genotype and
subtype both in clinical trials and practice. Commercial assays
have been developed, most of them targeting the 59 noncoding
region (59NCR) of the HCV genome, although this region is the
most conserved one. These methods have been shown to
differentiate well the different HCV genotypes (1 to 6), except
genotype 1 from genotype 6, a rare HCV genotype in the Western
world [23,24]. The goal of our study was to assess the ability of
molecular methods targeting the 59NCR to correctly identify the
HCV genotype 1 subtype in patients eligible for clinical trials, and
to identify the best method for this purpose.
Results
Hepatitis C Virus Genotype and Subtype Determination
by Phylogenetic Analysis of a Portion of the NS5B Gene
Direct sequence analysis of a sufficiently long portion of the
NS5B gene followed by phylogenetic analysis is the reference
method for identification of HCV genotype and subtype [1,25]. It
was used to identify the HCV genotype and subtype in 516
treatment-naı ¨ve patients included in a multicenter clinical trial
assessing different schedules of pegylated IFN-a2a and ribavirin
[26]. All of these patients were thought to be infected with HCV
genotype 1 at inclusion based on local assessment. In fact, 6
patients were infected with genotype 6, including 2 with subtype
6e, one with subtype 6o, one with subtype 6p, one with subtype 6q
and one with subtype 6r. These 6 samples were not considered for
further analysis in the present study. The remaining 510 patients
were confirmed to be infected with HCV genotype 1: 237 of them
(46.5%) were infected with HCV subtype 1a and 263 (51.6%) with
subtype 1b (Figure 1). As shown in Figure 1, HCV subtype 1a
strains segregated into two distinct clades, that were termed 1a
clade I (n=83, 35.0%) and 1a clade II (n=154, 65.0%). Eight
patients (1.6%) were infected with another HCV genotype 1
subtype, including 4 patients with subtype 1d, 2 with subtype 1e,
one with subtype 1i, and one with subtype 1l. The remaining 2
patients (0.3%) were infected with genotype 1 but the subtype
could not be determined. The ability of the different molecular
methods to correctly identify HCV subtypes 1a and 1b was then
tested on the 237 and 263 samples containing HCV subtypes 1a
and 1b, respectively.
Ability of Commercial HCV Genotype/Subtype
Determination Methods to Correctly Identify HCV
Subtypes 1a and 1b
Table 1 shows the proportion of HCV subtype 1a and 1b
samples that were correctly identified by the molecular methods
tested in this study. The results are shown globally, and after
removing the samples that could not be amplified with the PCR
technique used in the assay.
Methods based on the sole analysis of the 59NCR, namely
Trugene HCV Genotyping Kit and INNO-LiPA HCV 1.0, failed
to correctly identify HCV subtype 1a in 22.8% and 29.5% of
cases, and HCV subtype 1b in 9.5% and 8.7% of cases,
respectively (Table 1). Only 7 and 4 samples, respectively, could
not be PCR-amplified by these methods. Thus, the failure to
correctly identify the HCV subtype was due to erroneous
classification in the vast majority of these cases (Table 1). Two
(2.5%) and 14 (17.3%) of the 81 strains belonging to subtype 1a
clade I that could be PCR-amplified were incorrectly subtyped by
Trugene HCV Genotyping Kit and INNO-LiPA HCV 1.0,
respectively. On the other hand, 50 (32.7%) and 55 (35.9%) of the
153 strains belonging to subtype 1a clade II that could be PCR-
amplified were incorrectly classified by these two methods,
respectively. Table 2 shows the results given by the two methods
targeting the 59NCR only, Trugene HCV Genotyping Kit and
INNO-LiPA HCV 1.0, in the samples that were not correctly
classified as either 1a or 1b by these methods.
INNO-LiPA HCV 2.0 displays the same 59NCR oligonucleo-
tide probes as INNO-LiPA HCV 1.0, plus core-encoded
oligonucleotide probes aimed at better discriminating between
HCV subtypes 1a and 1b. With INNO-LiPA HCV 2.0, subtype
identification was corrected in 64 of the 70 subtypes 1a that were
incorrectly typed with INNO-LiPA HCV 1.0. Five samples could
not be PCR-amplified in the core-coding region and the result was
not interpretable with INNO-LiPA HCV 2.0 in the remaining
HCV Genotype 1 Subtyping
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identification in 13 of 23 subtypes 1b that were incorrectly typed
with INNO-LiPA HCV 1.0. Eight samples could not be PCR-
amplified in the core-coding region and the result was not
interpretable with INNO-LiPA HCV 2.0 in the remaining two
cases (Table 1). Overall, the second-generation line probe assay
correctly classified 97.5% of subtype 1a and 96.2% of subtype 1b
strains. When only samples that could be PCR-amplified with the
assay procedure were taken into account, correct subtype
determination was achieved in 99.6% and 99.2% of cases,
respectively (Table 1).
The real-time PCR-based assay targeting both the 59NCR and
the NS5B region, Abbott RealTime HCV Genotype II assay,
correctly identified 93.2% of subtype 1a and 88.9% of subtype 1b
strains. Only 2 HCV subtype 1b samples could not be PCR-
amplified with this method (Table 1).
59NCR Sequence Analysis in Misclassified Subtype 1a
Strains
Among the HCV subtype 1a strains, 47 were misclassified as
subtype 1b by Trugene HCV Genotyping Kit and/or INNO-
LiPA HCV 1.0, including 33 that were misclassified by both
assays, 7 that were misclassified by Trugene HCV Genotyping Kit
only, and 7 that were misclassified by INNO-LiPA HCV 1.0 only
(Table 2). Figure 2 shows an alignment of their 59NCR sequences
relative to the consensus sequences of the correctly classified
strains (including subtype 1a clade I, subtype 1a clade II and
subtype 1b). As shown in Figure 2, misclassification of subtype 1a
Table 1. Ability of the different molecular methods tested in this study to correctly identify HCV subtypes 1a and 1b in a series of
500 patients infected by one or the other of these subtypes.
Assay
Trugene HCV 59NC
Genotyping Assay INNO-LiPA HCV 1.0 INNO-LiPA HCV 2.0
Abbott RealTime HCV
Genotype II assay
Manufacturer
Siemens Medical
Solutions Diagnostic Innogenetics Innogenetics Abbott Molecular
Method
Sequence analysis
of the 59NCR followed
by sequence
comparison
Reverse
hybridization
targeting
the 59NCR
Reverse hybridiza-
tion targeting the
59NCR and the
core-coding region
Real-time PCR
assay targeting
the 59NCR and
NS5B-coding region
All samples Subtype 1a* (N=237), n/N (%) 183/237 (77.2%) 167/237 (70.5%) 231/237 (97.5%) 220/236** (93.2%)
Subtype 1b* (N=263), n/N (%) 238/263 (90.5%) 240/263 (91.3%) 253/263 (96.2%) 232/261** (88.9%)
Samples that
could be PCR-
amplified only
Subtype 1a*, n/N (%) 183/235(77.9%) 167/236 (70.8%) 231/232 (99.6%) 220/236 (93.2%)
Subtype 1b*, n/N (%) 238/258 (92.2%) 240/260 (92.3%) 253/255 (99.2%) 232/259 (89.6%)
Correct identification with the different techniques tested is shown for all samples, and for samples that could be amplified by PCR in the assay.
*The correct HCV genotype 1 subtype was identified by means of direct sequence analysis of a portion of the NS5B gene followed by phylogenetic analysis, the
reference method.
**In one 1a case and two 1b cases, not enough serum volume was available for testing in the Abbott RealTime HCV Genotype II assay.
doi:10.1371/journal.pone.0008209.t001
Figure 1. Phylogenetic tree plotted with NS5B sequences (nucleotide positions 8325-8610) from the 237 HCV subtype 1a and 263
HCV subtype 1b strains. HCV subtype 1a strains segregated into two distinct clades, termed 1a clade I and 1a clade II.
doi:10.1371/journal.pone.0008209.g001
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presence of natural polymorphisms at nucleotide positions 204 and
243, both of which are located within the sequence of an INNO-
LiPA HCV 1.0 probe. At position 243, A is the most frequent
nucleotide in HCV subtype 1a, in both subtype 1a clade I and
clade II. Substitution into a G, the most frequent nucleotide at
position 243 in subtype 1b, was found in all cases that were
misclassified as subtype 1b by Trugene HCV Genotyping Kit
and/or INNO-LiPA HCV 1.0 (Figure 2). At position 204, A is the
most frequent nucleotide for subtype 1a clade I, whereas C is the
most frequent nucleotide for subtype 1a clade II, and C or T are
the most frequent nucleotides for subtype 1b. In spite of the
presence of a G at position 243, the presence of an A at position
204 allowed correct identification of subtype 1a with Trugene
HCV Genotyping Kit but not with INNO-LiPA HCV 1.0
(Figure 2). The usual presence of a C at position 204 in subtype
1a clade II explains why misclassifications were far more frequent
with this clade than with subtype 1a clade I.
Among the 12 subtype 1a strains that were classified as
genotype 1, indeterminate subtype with Trugene HCV Genotyp-
ing Kit, one had a G and 5 had mixed A and G populations at
position 243. Two additional patients with an A at position 243
had a C at position 248. In the remaining 4 cases, no explanation
was found in the 59NCR sequence for the failure to identify the
HCV subtype (data not shown). Among the 25 subtype 1a strains
that were classified as genotype 1, indeterminate subtype with
INNO-LiPA HCV 1.0 (including 6 with the same profile in
Trugene HCV Genotyping Kit), 4 had a G and 4 had mixed A
and G populations at position 243. Three additional patients with
an A at position 243 had a C at position 248 (C only in two of
them, a mixture of C and T in one). In the 14 remaining cases, no
explanation was found in the 59NCR sequence for the failure to
identify the HCV subtype (data not shown).
59NCR Sequence Analysis in Misclassified Subtype 1b
Strains
Among HCV subtype 1b strains, 8 were misclassified as subtype
1a by Trugene HCV Genotyping Kit and/or INNO-LiPA HCV
1.0, including 3 that were misclassified by both assays, 4 that were
misclassified by Trugene HCV Genotyping Kit only, and 1 that
was misclassified by INNO-LiPA HCV 1.0 only (Table 2). Figure 3
shows an alignment of their 59NCR sequences relative to the
consensus sequences of the correctly classified subtype 1a and
subtype 1b strains. As shown in Figure 3, and as for misclassified
subtype 1a strains discussed above, misclassification of subtype 1b
strains into subtype 1a was related to the presence of natural
polymorphisms at positions 204 and 243. At position 243, G is the
most frequent nucleotide in HCV subtype 1b. Substitution into an
A, the most frequent nucleotide at position 243 in subtype 1a, was
found in all cases that were misclassified as subtype 1a by both
Trugene HCV Genotyping Kit and INNO-LiPA HCV 1.0 and by
INNO-LiPA HCV 1.0 only, but not in those that were
misclassified by Trugene HCV Genotyping Kit only (Figure 3).
In the latter, it is the presence of an A at position 204 instead of a
C or a T that was responsible for misclassification in all but one
case (Figure 3).
Among the 11 subtype 1b strains that were classified as
genotype 1, indeterminate subtype with Trugene HCV Genotyp-
ing Kit, one had an A at position 243. In the remaining cases, no
explanation was found in the 59NCR sequence for the failure to
identify the HCV subtype (data not shown). Among the 15 subtype
1b strains that were classified as genotype 1, indeterminate subtype
with INNO-LiPA HCV 1.0 (none of which were classified as
indeterminate in Trugene HCV Genotyping Kit), one had an A
and one harbored mixed A and G populations at position 243.
Both of them had a C at position 248 (C only in one of them and a
mixture of C and T in the other one). In the remaining 13 cases,
no explanation was found in the 59NCR sequence for the failure to
identify the HCV subtype (data not shown).
Incorrect Subtyping with Abbott RealTimeH C V
Genotype II Assay, that Targets Both the 59NCR and NS5B
Region
Among the HCV subtype 1a strains, 16 were incorrectly
classified by Abbott RealTime HCV Genotype II assay (Table 1): 2
were misclassified as subtype 1b, 12 were classified as genotype 1,
indeterminate subtype, one was identified as a mixed 1a/1b
infection, and one gave an indeterminate result. In one case, PCR
amplification failed, and in one case, not enough serum volume
was available for testing.
Among the HCV subtype 1b strains, 27 were incorrectly
classified by Abbott RealTime HCV Genotype II assay (Table 1): 3
were misclassified as subtype 1a, 18 were classified as genotype 1,
indeterminate subtype, 5 were identified as a mixed 1a/1b
Table 2. Number of samples displaying discrepancies between the assays targeting the 59NCR only and the reference method in
the 500 samples infected with either subtype 1a or subtype 1b.
Result with the reference method Result with the 59NCR targeting method Trugene HCV 59NC Genotyping Assay INNO-LiPA HCV 1.0
HCV subtype 1a Subtype 1b
Subtype 1a or 1b*
Genotype 1, indeterminate subtype
Genotype 1, other subtype
Other genotype
Result not interpretable
Negative PCR amplification
40
0
12
0
0
0
2
40
4
25
0
0
0
1
HCV subtype 1b Subtype 1a
Subtype 1a or 1b*
Genotype 1, indeterminate subtype
Genotype 1, other subtype
Other genotype
Result not interpretable
Negative PCR amplification
7
0
11
0
1
1
5
4
1
15
0
0
0
3
*The assay has been unable to differentiate between subtypes 1a and 1b.
doi:10.1371/journal.pone.0008209.t002
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PLoS ONE | www.plosone.org 4 December 2009 | Volume 4 | Issue 12 | e8209Figure 2. Alignment of the 59NCR sequences from the subtype 1a strains that were incorrectly classified by Trugene HCV
Genotyping Kit and/or INNO-LiPA HCV 1.0 relative to the consensus sequences of the correctly classified strains, including subtype
1a clade I (1a-I), subtype 1a clade II (1a-II) and subtype 1b. Positions 107, 204 and 243, that differentiate subtypes 1a and 1b are in bold. The
dotted squares represent the location of the INNO-LiPA HCV 1.0 oligonucleotide probes. The result given by each assay is shown on the right.
doi:10.1371/journal.pone.0008209.g002
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amplification failed, and in one case, not enough serum volume
was available for testing.
Discussion
HCV genotype determination is needed in clinical practice to
decide the dose of ribavirin and the duration of pegylated IFN-a-
ribavirin treatment [5]. In contrast, subtype identification has no
clinical impact on current therapy. However, this is changing with
the development of new specific inhibitors of HCV enzymes and
functions that may yield different antiviral responses and resistance
profiles according to the HCV genotype subtype
[13,14,15,16,17,18,19,20,21,22]. Correct HCV genotype 1 sub-
type identification is mandatory in clinical trials where these drugs
are tested alone, in combination, or in combination with pegylated
IFN-a and ribavirin for stratification and interpretation purposes.
It might also become necessary in future clinical practice when
several of these drugs have reached the market and a number of
treatment choices are available for HCV-infected patients.
In this context, the goal of our study was to identify the
appropriate molecular tool(s) for accurate HCV genotype 1
subtype determination in clinical trials and future practice. Our
study was performed in a large cohort of 500 treatment-naı ¨ve
patients eligible for HCV drug clinical trials and infected with
either subtype 1a or 1b, based on the reference method, i.e. direct
sequence analysis of the NS5B region followed by phylogenetic
analysis [1,27]. The results clearly show that, although they are by
far the most widely used techniques in new HCV drug
development trials, genotyping techniques based on the sole
analysis of the 59NCR should be avoided, as they mistype
approximately 25% and 10% of HCV subtype 1a and 1b strains,
respectively.
The accuracy of genotype and subtype determination depends
on the amount of information (i.e. the number of informative sites)
that is utilized for discrimination in the tested region. Our results
show that only three positions in the 59NCR can be used to
discriminate HCV subtypes 1a and 1b, including positions 107,
204 and 243, and that natural polymorphisms at these positions
are responsible for mis-subtyping with methods analyzing
exclusively the 59NCR. Indeed, all of these positions are located
within the sequence of INNO-LiPA HCV 1.0 oligonucleotide
probes and they are used in the sequence comparison algorithms
of Trugene HCV Genotyping Kit. The presence of a substitution
at position 243 has already been reported to yield mistyping with
methods targeting the 59NCR [28,29]. We show here that
polymorphisms at position 204 also play a role. Additional
changes at position 248 could also play a role in mis-subtyping
as they were observed in several patients who had no
polymorphism at position 243. In addition, analysis of the
59NCR has been reported not to discriminate well between
HCV genotype 1 and genotype 6, subtypes c to l [28,30,31,32].
This explains why some patients, initially included in this trial as
they were considered to be infected with HCV genotype 1, were in
fact infected with HCV genotype 6.
Novel assays have been recently developed that aim at better
discriminating among the different HCV genotype 1 subtypes and
between genotypes 1 and 6. Abbott RealTime HCV Genotype II
assay is a real-time PCR method using several sets of genotype-
and subtype-specific primers and probes located in both the
Figure 3. Alignment of the 59NCR sequences from the subtype 1b strains that were incorrectly classified by Trugene HCV
Genotyping Kit and/or INNO-LiPA HCV 1.0 relative to the consensus sequences of the correctly classified strains, including subtype
1a clade I, subtype 1a clade II and subtype 1b. Positions 107, 204 and 243, that differentiate subtypes 1a and 1b are in bold. The dotted squares
represent the location of the INNO-LiPA HCV 1.0 oligonucleotide probes. The result given by each assay is shown on the right.
doi:10.1371/journal.pone.0008209.g003
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a second target region for analysis led to substantially improving
HCV genotype 1 subtype identification compared to methods
targeting the sole 59NCR. However, in contrast with a previous
report [33], we found that this assay failed to correctly identify
HCV genotype 1 subtype in approximately 10% of cases. No
obvious explanation was found when comparing the NS5B
sequences of these strains with those that were correctly classified.
However, in contrast with direct sequence analysis of the NS5B
gene, which uses a long nucleotide sequence, the real-time PCR
assay uses only the short sequence of its primers and probes. This
probably explains that this assay may sometimes fail to
differentiate HCV genotype 1 and several subtypes of genotype
6 (M. Bouvier-Alias, unpublished data). Improvement in the
sequence of the primers and probes in order to correctly classify
HCV subtypes 1a and 1b is underway in order to make this assay a
useful tool for clinical trials and practice.
In the second-generation line probe assay, probes targeting the
core-coding region were added to the probes targeting the 59NCR
already present in the first-generation assay, and a new PCR
reaction was implemented to allow multiplex amplification of both
regions. The goal was to improve discrimination between subtypes
1a and 1b and between genotypes 1 and 6. Better performance of
INNO-LiPA HCV 2.0 than the first-generation assay has already
been reported [30,32]. We show here that, when excluding the
small number of samples that could not be amplified with the PCR
technique provided in the kit, correct identification of HCV
subtypes 1a and 1b was achieved in more than 99% of cases.
Therefore, INNO-LiPA HCV 2.0 currently is the best available
commercial assay for HCV genotype 1 subtype identification and
should be used in clinical trials and practice.
The ability of the tested assays to detect simultaneous infections
by different HCV genotype 1 subtypes was not evaluated.
However, the line probe assays have been shown to be more
sensitive for the detection of multiple genotype infections than
sequence-based assays, as they can detect minor viral populations
representing more than 5%–10% of the total population [23]. This
information is not yet available for the real-time PCR-based assay.
In conclusion, the choice of the target genome region, more
than the technology, is crucial for HCV genotyping/subtyping. In
the context of new HCV drug development, where correct HCV
genotype 1 subtype determination is mandatory, HCV genotyping
methods based on the exclusive analysis of the 59NCR should be
avoided because they poorly discriminate among these subtypes.
The second-generation line probe assay is currently the best
commercial assay for determination of HCV genotype 1 subtypes
1a and 1b. It can therefore be used locally in clinical trials to
identify the HCV subtype and stratify the patients at inclusion, as
well as to interpret efficacy and resistance data. When reporting
final data, direct sequence analysis of the NS5B region and/or
another coding region (for instance the region encoding the
antiviral drug target HCV protein) should always be performed as
it may identify mistyping or mis-subtyping with commercial assays,
especially in the case of rare subtypes.
Materials and Methods
Materials
A total of 516 treatment-naı ¨ve patients infected with HCV
genotype 1 included in a French multicenter clinical trial of
pegylated IFN-a and ribavirin were studied. The characteristics of
the patients have been previously described [26]. The protocol was
approved by the local Ethics Committee (Comite ´ Consultatif de
Protection des Personnes dans la Recherche Biome ´dicale,
CCPPRB) of the University Hospital of Nancy on October 24,
2000. All patients provided written informed consent. The study
was conducted according to the guidelines of the Declaration of
Helsinki, under provisions of Good Clinical Practices, or both.
Data was collected by the study group, and analyzed by the
authors with the help of the sponsor. The authors had unlimited
access to the data and no limitation on publication was imposed by
any party.
All patients had anti-HCV antibodies in serum, detectable
serum HCV RNA (.600 IU/mL), increased alanine aminotrans-
ferase (ALT) levels on at least two determinations within the
previous 6 months, liver biopsy findings consistent with chronic
hepatitis C within 18 months before therapy, and compensated
liver disease.
The clinical specimens used in the present study were the
baseline serum samples from the 516 patients. The average HCV
RNA level was 6.260.8 Log10 IU/mL and 70.2% of the samples
had a high HCV RNA, .800,000 IU/mL (5.9 Log10 IU/mL)
[26]. Sera were frozen at 270uC until use in this study.
Study Design
The patients had been initially considered to be infected with
HCV genotype 1 and included in the study based on a local
determination of the HCV genotype and, eventually, subtype. In
the present study, the exact genotype and subtype were
determined by means of the reference method, i.e. direct sequence
analysis of a portion of the nonstructural (NS) 5B-coding gene
followed by phylogenetic analysis. The ability of the following
commercial assays to correctly identify HCV subtypes 1a and 1b
was assessed, in comparison with the reference method: i) an assay
based on direct sequence analysis of the 59NCR of HCV genome,
Trugene HCV 59NC Genotyping Kit (Siemens Medical Solutions
Diagnostics, Tarrytown, New York); ii) the first-generation Line
Probe Assay, INNO-LiPA HCV 1.0 (Innogenetics, Gent,
Belgium), based on reverse-hybridization of PCR products using
oligonucleotide probes in the 59NCR; iii) the second-generation
Line Probe Assay, INNO-LiPA HCV 2.0 (Innogenetics), based on
reverse-hybridization of PCR products using oligonucleotide
probes in the 59NCR and the core-coding region; iv) A real-time
PCR-based assay using primers and probes in both the 59NCR
and the NS5B-coding region, Abbott RealTime HCV Genotype II
assay (Abbott Molecular, Des Plaines, Illinois).
Direct Sequence Analysis of a Portion of the NS5B Gene
Followed by Phylogenetic Analysis (Reference Method)
Briefly, total RNA was extracted from 200 ml of serum by using
the High Pure Viral RNA kit (Roche Molecular Biochemicals,
Mannheim, Germany), according to the manufacturer’s instruc-
tions. The RNA pellet was eluted with 50 ml of diethyl
pyrocarbonate-treated (DEPC) water and stored at 270uC until
analysis. Complementary DNA (cDNA) synthesis was performed
with 5 ml of total extracted RNA and 200 U of Superscript III
reverse transcriptase (Invitrogen, Carlsbad, California). A nested
PCR technique was used to amplify a DNA fragment located in
the NS5B gene. The first round used external sense and antisense
primers Sn755 and Asn1121 [34] and consisted of 35 PCR cycles
at 95uC for 30 s, 58uC for 30 s, and 70uC for 30 s. The second
round used internal sense primer NS5B–SI766 and antisense
primer NS5B–ASI1110 [26] and consisted of 35 cycles at 95uC for
30 s, 58uC for 30 s, and 70uC for 30 s. PCR products were
directly sequenced with the Big-Dye Terminator Cycle v3.1
sequencing kit on an ABI 3100 sequencer (Applied Biosystems,
Foster City, California), according to the manufacturer’s instruc-
tions. Phylogenetic analyses were carried out using genotypes 1 to
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Phylogeny Inference Package (PHYLIP), version 3.65 [35].
Nucleotide sequences (286 bp) long were aligned with the
reference sequences using CLUSTAL W [36]. Phylogenetic
relationships were deduced by means of DNADIST-NEIGHBOR
from PHYLIP. For neighbor-joining analysis, a Kimura 2-
parameter distance matrix with a transition/transversion ratio
(Ts/Tv) of 2.0 was used [37]. Phylogenetic trees were plotted with
NJPlot and the figure was drawn with Dendroscope v2.3 (www.
dendroscope.org) [38,39]. Their robustness was assessed by
bootstrap analysis of 1000 replicates by means of the SEQBOOT
program from PHYLIP.
Direct Sequence Analysis of the 59NCR
For direct sequence analysis of the 59NCR, The Trugene
HCV 59NC Genotyping Kit was used. This assay is based on
semi-automated CLIP
TM sequencing of the 59 NCR. Briefly,
total extracted RNA was used as a template for reverse
transcription-PCR amplification in a single tube. A 244-bp
fragment spanning nucleotide positions 68–311 in the 59NCR
(according to strain H77) was amplified. The reaction consisted
of a ‘‘hot-start’’ protocol with an initial reverse transcription at
50uC for 30 min, a PCR activation step at 95uC for 15 min, 35
cycles at 95uC for 30 s, 55uC for 30 s, and 72uCf o r1m i n ,a n d
a final elongation at 72uC for 7 min. The amplified product
was then labeled via the CLIP
TM sequencing reaction. Briefly,
bidirectional DNA sequencing was performed using two
sequencing primers labeled with different fluorescent dyes,
followed by electrophoresis and data analysis on the Open-
GeneH DNA sequencing system (Siemens Medical Solutions
Diagnostics). For final interpretation, each bidirectional se-
quence was automatically aligned with a panel of more than
100 reference sequences with the GeneLibrarian
TM module of
the GeneObjects
TM software (Siemens Medical Solutions
Diagnostics), allowing genotype and subtype assignment based
on percent sequence identity.
Reverse Hybridization after PCR Amplification
The INNO-LiPA HCV 2.0 assay (Innogenetics) is provided with
reagents for PCR amplification of two fragments spanning two
thirds of the 59NCR and a portion of the core-coding region,
respectively. The products amplified with this method were used
for hybridization with both INNO-LiPA HCV 1.0 and INNO-
LiPA HCV 2.0 strips.
Briefly, reverse transcription-PCR was performed in a single
tube. Twenty ml of extracted RNA was added to 30 mlo fP C R
master mix containing two pairs of biotinylated synthetic
oligonucleotides corresponding to the two amplified regions.
Reverse transcription was performed at 50uC for 30 min,
followed by an initial PCR activation step of 95uC for 15 min.
Then, 40 cycles of 95uC for 30 s, 50uC for 30 s, and 72uCf o r
15 s were carried out, with a final extension at 72uCf o r2m i n
on a UNO-Thermoblock
TM (Biometra, Goettingen, Germany).
Two distinct biotinylated DNA fragments of 240 and 270 bp
representing the 59NCR and core-coding region, respectively,
were produced.
After denaturation, the biotinylated PCR products were
hybridized to oligonucleotide probes bound to the INNO-LiPA
HCV 1.0 and INNO-LiPA HCV 2.0 nitrocellulose strip,
respectively. INNO-LiPA HCV 1.0 contains two control lines
and 19 59NCR DNA probe lines specific for the different HCV
genotypes and subtypes. INNO-LiPA HCV 2.0 contains the same
lines, plus an additional core control line and three core DNA
probe lines, specific for HCV genotype 1 subtypes and genotype 6.
After the hybridization step, the unhybridized PCR product was
washed from the strip, and alkaline phosphatase-labeled strepta-
vidin (conjugate) was bound to the biotinylated hybrid. 5-bromo-4-
chloro-3-indolylphosphate (BCIP)-nitroblue tetrazolium chromo-
gen (substrate) reacts with the streptavidin-alkaline phosphate
complex, forming a purple-brown precipitate, resulting in a visible
banding pattern on the strip. AutoLiPA 2.0 (Innogenetics,
Zwijndrecht, Belgium) was used to carry out hybridization and
the developing color step.
Real-Time PCR Determination of the HCV Genotype
The Abbott RealTime HCV Genotype II assay (Abbott
Diagnostic) is based on real-time PCR amplification targeting
two genome regions: the 59NCR and the NS5B-coding region.
The assay uses 4 primer pairs and the corresponding probes
labeled with different fluorescent dyes: one pair targets the 59NCR
and is used for amplification of all HCV strains; the second and
third pairs target the NS5B-coding region and are used to
specifically amplify HCV subtype 1a and 1b strains, respectively;
the fourth pair is used for amplification of the internal control.
Briefly, HCV RNA was extracted from 200 ml of serum with the
m2000SP automated device (Abbott Molecular), according to the
manufacturer’s protocol. The PCR reactions were run in the
m2000RT automated device (Abbott Molecular). Three separate
real-time PCR reactions (A, B and C) were run in parallel for each
strain. The first step was reverse transcription by means of the rTth
enzyme, followed by the PCR reaction that targets both 59NCR
and NS5B in reactions A and B, and only 59NCR in reaction C.
Probes labeled with different fluorophores were used in each PCR
reaction to confirm the presence of HCV RNA; identify HCV
subtype 1a and HCV genotype 3 (reaction A); identify HCV
genotypes 1 and 2 and HCV subtype 1b (reaction B); identify
HCV genotypes 4, 5 and 6 (reaction C). The assay was performed
according to the manufacturer’s instructions. Indeterminate results
were retested from a serum volume of 500 ml.
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